News
J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback